Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [5]. - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must move the court by December 15, 2025 [4]. - The lawsuit alleges that Baxter misled investors regarding the safety and efficacy of its Novum IQ Large Volume Pump, which suffered systemic defects leading to serious patient risks [6]. Group 2: Allegations Against Baxter - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [6]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to continued harm [6]. - The allegations suggest that Baxter's statements about the product's safety, efficacy, and sales prospects were materially false and misleading, resulting in investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing shareholder interests [5].

New York, New York--(Newsfile Corp. - November 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for misrepresentations regarding the market demand and launch of its sleep apnea device, Inspire V, during the specified Class Period [2][6]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Inspire Medical common stock between August 6, 2024, and August 4, 2025 [2]. - Defendants allegedly made materially false and misleading statements about the demand for Inspire V and the company's readiness for its launch, leading to investor damages when the truth was revealed [6]. Group 2: Investor Information - Investors who purchased Inspire Medical common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must act before the deadline of January 5, 2026, to serve as lead plaintiff [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [5]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 15, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against MoonLake - The complaint alleges that during the class period, the defendants made false or misleading statements and failed to disclose material facts regarding the differences between Nanobodies and monoclonal antibodies [5]. - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's Nanobody structure does not provide superior clinical benefits compared to BIMZELX [5]. - The lawsuit asserts that when the true information became public, investors suffered damages due to the misleading statements made by the defendants [5].

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Quanex Building Products Corporation Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - NXNovember 10, 2025 12:55 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quanex Building Products Corporation (NYSE: NX) between December 12, 2024 and September 5, 2025, ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Marex Group plc to secure legal counsel before the December 8, 2025 deadline for a securities class action lawsuit related to the company's misleading financial statements and practices [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Marex securities between May 16, 2024, and August 5, 2025, and they may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 8, 2025, to represent other class members [3][5]. Group 2: Allegations Against Marex - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements between subsidiaries and related parties [5]. - As a result of these actions, Marex's financial statements were deemed unreliable, and positive statements about the company's business and prospects were misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is urging investors of Lantheus Holdings, Inc. to secure legal counsel before the November 10, 2025 deadline for a securities class action lawsuit related to the company's performance during the specified class period [1][3]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by the November 10, 2025 deadline to serve as lead plaintiff [3][5]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy, which ultimately harmed investors when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Freeport securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Freeport [2]. Group 2: Incident Impact - On September 24, 2025, Freeport released an update regarding a mud rush incident at the Grasberg Block Cave mine in Indonesia, which resulted in the fatal injuries of two team members [3]. - Following the announcement of this incident, Freeport's stock experienced a significant decline of 16.95% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for its clients [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers and acquirers of Synopsys, Inc. securities for the period between December 4, 2024, and September 9, 2025, due to alleged misleading statements and failure to disclose material adverse facts about the company's business and operations [1][5]. Group 1: Lawsuit Details - The lawsuit claims that during the Class Period, Synopsys made materially false and misleading statements regarding its business focus on artificial intelligence customers, which negatively impacted its Design IP business economics [5]. - Defendants allegedly failed to disclose that certain decisions regarding road maps and resources were unlikely to yield intended results, leading to a material negative impact on financial results [5]. - The lawsuit asserts that the positive statements made by the defendants about Synopsys' business lacked a reasonable basis and were materially misleading [5]. Group 2: Participation Information - Investors who purchased Synopsys securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by December 30, 2025, to represent other class members in directing the litigation [1][3].